摘要
将80例流行性腮腺炎患者随机分成2组,对照组和实验组各40例;对照组静滴利巴韦林15 mg/(kg.d),治疗组静滴利巴韦林15 mg/(kg.d)与炎琥宁10 mg/(kg.d),实验组和对照组疗程均为1周。疗程结束后,实验组总有效率97.50%(39/40),对照组为80.00%(32/40),两组疗效差异有统计学意义。炎琥宁联合利巴韦林治疗流行性腮腺炎可明显提高疗效,值得临床推广。
Eighty patients with mumps were divided into a control group （n=40） and a treatment group （n=40）. The control group was treated with ribavirin 15 mg/（kg ·d） by intravenous drip while the treatment group was treated with yanhuning （potassium sodium dehydroandrographolide succinate） 10 mg/kg, d and ribavirin 15 mg/（kg · d） in the same manner. The course was 1 week. At the end of treatment, total efficacy was 97.5% （39/40） in the treatment group and 80.0% （32/40）in the control group. There was a significant difference between the two groups. The therapeutic effect of ribavirin in treating mumps can be enhanced with yanhuning combined, warranting the clinical use of yanhuning.
出处
《中国病原生物学杂志》
CSCD
2010年第2期156-157,共2页
Journal of Pathogen Biology
关键词
流行性腮腺炎
炎琥宁
利巴韦林
疗效
Mumps
yanhuning （potassium sodium dehydroandrographolide succinate）
ribavirin
therapeutic effect
